Fluticasone-umeclidinium-vilanterol

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: fluticasone-umeclidinium-vilanterol · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Inhaled; no known interaction.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Severe COPDCO 2.5(A)(2)

05 Sources

Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate) Pow · FDA label (DailyMed)

Report an error in this record →